1 278

Cited 0 times in

Methylation-Dependent Loss of RIP3 Expression in Cancer Represses Programmed Necrosis in Response to Chemotherapeutics

Authors
Koo, Gi-Bang; Morgan, Michael J.; Lee, Da-Gyum; Kim, Da-Gyum; Yoon, Jung-Ho; Koo, Ja Seung; Kim, Seung Il; Kim, Soo Jung; Son, Mi Kwon; Hong, Soon Sun; Levy, Jean M. Mulcahy; Pollyea, Daniel A.; Jordan, Craig T.; Yan, Pearlly; Frankhouser, David; Nicolet, Deedra; Maharry, Kati; Marcucci, Guido; Choi, Kyeong Sook; Cho, Hyeseong; Thorburn, Andrew; Kim, You-Sun
Department
Department of Biochemistry & Molecular Biology
Abstract
Receptor-interacting protein kinase-3 (RIP3, or RIPK3) is an essential part of the cellular machinery that executes “programmed”, or “regulated”, necrosis. Here we show that programmed necrosis is activated in response to many chemotherapeutic agents and contributes to chemotherapy-induced cell death. However, we show RIP3 expression is often silenced in cancer cells due to genomic methylation near its transcriptional start site, so RIP3-dependent activation of MLKL and downstream programmed necrosis during chemotherapeutic death is largely repressed. Nevertheless, treatment with hypomethylating agents restores RIP3 expression, and thereby promotes sensitivity to chemotherapeutics in a RIP3-dependent manner. RIP3 expression is reduced in tumors when compared to normal tissue in 85% of breast cancer patients, suggesting that RIP3 deficiency is selected for during tumor growth/development. Since hypomethylating agents are reasonably well-tolerated in patients, we propose that RIP3-deficient cancer patients may benefit from receiving hypomethylating agents to induce RIP3 expression prior to treatment with conventional chemotherapeutics.
Appears in Collections:
Others > Poster > Poster
Export
RIS (EndNote)
XLS (Excel)
XML

qrcode

해당 아이템을 이메일로 공유하기 원하시면 인증을 거치시기 바랍니다.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse